December 2016
-
Pulmatrix has announced plans for clinical development of PUR3100, an iSPERSE dry powder formulation of dihydroergotamine (DHE) for the treatment of migraine, after a PK study in dogs showed exposure kinetics similar to those of… Read more . . .
-
Sorrento Therapeutics said that the FDA has cleared its IND for a Phase 1 study of STI-2099 intranasal neutralizing antibody (CoviDrops) in healthy volunteers and in patients with mild COVID-19. The company said that it… Read more . . .
-
According to Oyster Point Pharma, the FDA has accepted the company’s NDA for its OC-01 varenicline nasal spray for the treatment of dry eye disease and has set a PDUFA goal date of October 17,… Read more . . .
-
Cipla Limited announced that the FDA has issued final approval of an ANDA for the company’s generic version of GSK’s Imitrex 20 mg sumatriptan nasal spray. Cipla’s sumatriptan nasal spray is an AB-rated generic. Imitrex… Read more . . .
-
Impel NeuroPharma has named Leonard S. Paolillo as Chief Commercial Officer and Gerald F. Penn as VP, Market Access and Trade in anticipation of the launch of Trudhesa intranasal dihydroergotamine mesylate (DHE) for the treatment… Read more . . .
-
OINDP testing specialist Copley Scientific has announced upgrades to the company’s inhaler testing equipment range, including new products such as the Inhaler Testing Workstation (ITW) and updates to its TPK critical flow controllers, BAC 2100 breath… Read more . . .
-
Atossa Therapeutics announced that a two-week Phase 1 study evaluating the safety of two dose levels of the company’s AT-301 nasal spray in healthy volunteers demonstrated that the nasal spray was safe and well tolerated.… Read more . . .
-
Reflections by Philip Kuehl and Jacob McDonald, Lovelace Biomedical What a year! 2020 was the year when those of us in aerosol science were forced to stop compartmentalizing. It was the year that we could… Read more . . .
-
Virpax Pharmaceuticals said that the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health has begun pre-clinical studies of Virpax’s Envelta intranasal enkephalin to support an IND submission. Virpax signed a cooperative… Read more . . .
-
Starpharma said that it is set to launch its Viraleze astodrimer sodium antiviral nasal spray within the next month after receiving approval to market the nasal spray in Europe and the UK. In September 2020,… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK